<unk>  <unk> , also called<unk>  suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require<unk>  hormones, such as testosterone, to grow.<unk>  reduces the levels of<unk>  hormones, with drugs or surgery, to prevent the prostate cancer cells from growing. The pharmaceutical approaches include antiandrogens and chemical castration. Several studies have concluded that<unk>  has demonstrated benefit in patients with metastatic disease, and as an adjunct to radiation therapy in patients with locally advanced disease, as well as those with unfavorable intermediate-risk or high-risk localized disease. However, in patients with low-risk prostate cancer,<unk>  has demonstrated no survival advantage, and significant harm, such as impotence, diabetes and bone loss. The therapy can also eliminate cancer cells by inducing<unk>  deprivation-induced senescence. Lowering<unk>  levels or stopping them from getting into prostate cancer cells often makes prostate cancer shrink or grow more slowly for a time. However, this treatment needs to be combined with radiation therapy (RT) because<unk>  itself does not eradicate the cancer; it just decreases its aggressiveness.
Androgen deprivation therapy
Estrogen deprivation therapy
Hormone therapy
Masculinizing hormone therapy
Feminizing hormone therapy
Androgen replacement therapy
Hormonal therapy 
Prostate brachytherapy